Developing novel, immune-based therapies for medically unmet, life-threatening and life-limiting diseases

NovaBiotics Announces Publication of Data Elucidating NP339’s Broad Antifungal Activity in Antimicrobial Agents and Chemotherapy

Jun 1, 2021

Peer reviewed journal article highlights Company’s novel antifungal peptide’s activity against a broad range of fungal pathogens with no off target cytotoxicity Aberdeen, June 1, 2021. NovaBiotics Ltd, a privately held clinical stage company developing novel immune...

NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia

Randomized embedded multi-factorial platform trial to provide accelerated, real-world evidence in community acquired pneumonias including COVID-19, influenzas and bacterial pneumonias Aberdeen, June 21, 2021. NovaBiotics Ltd, a privately held clinical stage company...

NovaBiotics Announces Publication of Data Elucidating NP339’s Broad Antifungal Activity in Antimicrobial Agents and Chemotherapy

NovaBiotics attending the BIO Digital Meeting, June 2021

NovaBiotics are looking forward to participating at the upcoming BIO Digital Meeting taking place on June 10-11 & 14-18, 2021. The team are ready to meet with all interested parties and explain how we are using immunology to deliver novel therapies for...

Clear and unbiased facts about why the COVID 19/Pneumonia relationship is bad news

By Grant Ellis, Director, NovaBiotics Ltd A number of commentators are now saying that as a result of the vaccines, COVID 19 will be akin to flu – something that comes around every year but for most of us nothing more than an inconvenience and only severely...

Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics

Aberdeen, UK – 26th February 2021 – NovaBiotics Ltd, the clinical-stage anti-infectives biotechnology company, today announced that it has entered into a licensing agreement with an undisclosed partner to commercialise its NP213 peptide in a topical (brush/paint-on)...

NovaBiotics Attending BIO CEO & Investor Digital Conference

CEO Dr Deborah O'Neil and the NovaBiotics team will be attending the BIO CEO & Investor Conference, hosted by the Biotechnology Innovation Organization on the 16th-18th February 2021. Meet with us through the event portal BIO CEO & Investor Event to learn...

Just when we thought things were getting better…..

By Grant Ellis, Director NovaBiotics Ltd Back in October I quoted Sir Patrick Vallance, the government’s Chief Scientific Adviser saying that no vaccine for Covid was likely before the spring of 2021. We all now know that there are two vaccines that have been...

CARE CF 1 oral Lynovex clinical trial data published

NovaBiotics are delighted to announce that our CARE CF 1 phase 2b clinical trial data for oral Lynovex in infectious pulmonary exacerbations of cystic fibrosis is published today in PLOS ONE. Our findings further support the potential of Lynovex® as game-changer in CF...

NovaBiotics in the press

NovaBiotics featured in an article published in the Mail on Sunday on 27 December 2020 entitled “British scientists are engineering superbug-beating medications to fight off killer infections including MRSA.” See the full article by clicking Mail on Sunday Article 27...

As world antimicrobial awareness week gets underway, our CEO shares her thoughts on the near-term outlook for antimicrobials: the economic case aligning with innovation

To mark World Antimicrobial Awareness Week, Deborah O’Neil tells pharmaphorum why 2021 might be the year anti-infective drugs finally demonstrate their economic value. You can access full article here Pharmaphorum Article 18 Nov 2020

NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on leveraging its novel immunology platforms to design and develop first-in-class therapies to address difficult-to-treat, medically unmet diseases.

The Company’s advanced portfolio of therapeutic candidates target life-threatening and life-limiting diseases in the inflammation, infection and respiratory space.

NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 and operates from sites in Aberdeen, UK (R&D headquarters), Dublin, Ireland and Boston (MA), U.S. The Company has a successful track record of invention to initiation of phase 3 clinical trials of its portfolio of therapeutic candidates. These first in class molecules have been developed from NovaBiotics’ two proprietary Technology platforms which are underpinned by an extensive, wholly owned intellectual property estate.